Paul Chaplin, Bavarian Nordic CEO

Bavar­i­an Nordic's mon­key­pox vac­cine wins pos­i­tive opin­ion from EMA com­mit­tee

With de­mand ris­ing for Bavar­i­an Nordic’s small­pox vac­cine, Eu­ro­pean of­fi­cials have giv­en the thumbs up to ex­pand the la­bel to in­clude mon­key­pox.

Im­vanex, mar­ket­ed as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.